Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-Current Deffered Revenue: 2017-2018

Historic Non-Current Deffered Revenue for Puma Biotechnology (PBYI) over the last 2 years, with Dec 2018 value amounting to $5.8 million.

  • Puma Biotechnology's Non-Current Deffered Revenue rose 7.57% to $5.8 million in Q4 2018 from the same period last year, while for Dec 2018 it was $5.8 million, marking a year-over-year increase of 7.57%. This contributed to the annual value of $5.8 million for FY2018, which is 7.57% up from last year.
  • As of Q4 2018, Puma Biotechnology's Non-Current Deffered Revenue stood at $5.8 million, which was down 1.04% from $5.9 million recorded in Q3 2018.
  • Over the past 5 years, Puma Biotechnology's Non-Current Deffered Revenue peaked at $5.9 million during Q3 2018, and registered a low of $5.4 million during Q4 2017.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $5.5 million (2017), whereas its average is $5.6 million.
  • Data for Puma Biotechnology's Non-Current Deffered Revenue shows a peak YoY increased of 8.05% (in 2018) over the last 5 years.
  • Over the past 2 years, Puma Biotechnology's Non-Current Deffered Revenue (Quarterly) stood at $5.4 million in 2017, then increased by 7.57% to $5.8 million in 2018.
  • Its Non-Current Deffered Revenue stands at $5.8 million for Q4 2018, versus $5.9 million for Q3 2018 and $5.5 million for Q2 2018.